Abstract: A composition comprising: at least one organosilicon compound A comprising at least two identical or different hydrolyzable and condensable groups, or at least two silanol functions ?SiOH, at least one crosslinking agent B, optionally at least one filler C, and a catalytically effective amount of at least one polycondensation catalyst M which is a zinc complex comprising in its structure a first type of ligand that is a ?-diketonate and a second type of ligand that is an amine.

Abstract: The invention relates to an article with antifouling properties, intended for aquatic uses and, in particular, for marine uses, and to a method for slowing down the growth of aquatic organisms on submersible or semi-subermisible structures.

Abstract: The invention relates to an article with antifouling properties, intended for aquatic uses and, in particular, for marine uses, and to a method for slowing down the growth of aquatic organisms on submersible or semi-submersible structures.

Abstract: The present invention relates to an organopolysiloxane composition which is suitable for vulcanization into an elastomer as from room temperature, and which crosslinks via polycondensation, as well as to new organopolysiloxane polycondensation catalysts.

Abstract: The present invention relates to an organopolysiloxane composition which is suitable for vulcanisation into an elastomer as from room temperature, and which crosslinks via polycondensation, as well as to new organopolysiloxane polycondensation catalysts.

Abstract: The invention relates to an article with antifouling properties, intended for aquatic uses and, in particular, for marine uses, and to a method for slowing down the growth of aquatic organisms on submersible or semi-submersible structures.

Abstract: The invention relates to an article with antifouling properties, intended for aquatic uses and, in particular, for marine uses, and to a method for slowing down the growth of aquatic organisms on submersible or semi-subermisible structures.

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.